招商国证生物医药指数证券投资基金 基金管理人：招商基金管理有限公司 基金托管人：中国银行股份有限公司 送出日期：2025 年 8 月 28 日 招商国证生物医药指数证券投资基金 2025 年中期报告 基金管理人的董事会及董事保证本报告所载资料不存在虚假记载、误导性陈述或重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。本中期报告已经三分之二 以上独立董事签字同意，并由董事长签发。 基金托管人中国银行股份有限公司根据本基金合同规定，于 2025 年 8 月 27 日复核了本 报告中的财务指标、净值表现、利润分配情况、财务会计报告、投资组合报告等内容，保证 复核内容不存在虚假记载、误导性陈述或者重大遗漏。 基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定 盈利。 基金的过往业绩并不代表其未来表现。投资有风险，投资者在作出投资决策前应仔细阅 读本基金的招募说明书及其更新。 本报告中财务资料未经审计。 本报告期自 2025 年 1 月 1 日起至 6 月 30 日止。 第 1 页 共 58 页 招商国证生物医药指数证券投资基金 2025 年中期报告 第 2 页 共 58 页 ...

Core Viewpoint - The report provides an overview of the performance and management of the招商国证生物医药指数证券投资基金 for the second quarter of 2025, highlighting its investment strategy, financial indicators, and market conditions affecting the fund's performance [1][5]. Fund Product Overview - The fund is a passive index fund that aims to track the国证生物医药指数, utilizing a complete replication method to construct its stock portfolio based on the index's components and their weights [1][5]. - As of the end of the reporting period, the total fund shares amounted to approximately 24.03 billion [1]. Financial Indicators and Fund Performance - For the reporting period from April 1, 2025, to June 30, 2025, the A class share net value growth rate was 1.46%, while the C class share net value growth rate was 1.44%, both outperforming the benchmark growth rate of 0.90% [3][7]. - The fund's asset allocation included approximately 94.36% in stocks and 0.19% in bonds, indicating a strong focus on equity investments [5][8]. Investment Strategy - The fund employs a disciplined investment approach with quantitative risk management to achieve returns similar to the benchmark index [1][5]. - The management team actively monitors the fund's tracking deviation from the benchmark and adjusts the portfolio accordingly to optimize performance [1][5]. Market Conditions - The report notes significant market volatility influenced by factors such as overseas trade tensions and geopolitical conflicts, with the国证生物医药指数 increasing by 0.90% during the reporting period [7][8]. - The fund maintained a position of approximately 94.5% during the reporting period, effectively tracking the benchmark [7].